Trial Profile
A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 12 Nov 2018 Status changed from recruiting to discontinued.
- 20 Apr 2017 New trial record